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The ubiquitin proteasome system in human diseaseDr Rob Layfield has worked on the basic biology of the
small modifier protein ubiquitin, and in particular human
disorders of ubiquitin-mediated processes, since graduating
from the University of Nottingham in 1990. After working
as a post-doc with John Mayer, from 1997-2000 he held a
Research into Ageing Fellowship and in 2000 was awarded
a Wellcome Trust Research Career Development Fellow-
ship. As part of the latter he worked with Maria Spillantini
at the University of Cambidge. In 2000 he made the first
mechanistic connections between dysfunction of the
ubiquitin-proteasome system and Alzheimer's disease.
Current work includes structural and functional studies of
p62/SQSTM1, a protein which is mutated in the skeletal
disorder Paget's disease of bone. Significantly, recent research has shown that Paget's
disease (with SQSTM1 mutations) represent the archetypal example of human condition
associated with loss of function mutations in a ubiquitin-binding protein.The award of the Nobel Prize for Chemistry to Avram Hershko,
Aaron Ciechanover and Irwin Rose in 2004 for the discovery of
“ubiquitin-dependent protein degradation” was an appropriate
accolade for a major discovery in biochemistry in the second half of
the 20th century. It is now apparent that protein ubiquitylation/
deubiquitylation ranks with protein phosphorylation/dephosphoryla-
tion as an important post-translation modiﬁcation of proteins in the
regulation of cell physiology.
Proteins can be phosphorylated on serine, threonine, tyrosine and
histidine residues, whereas protein ubiquitylation occurs predomi-
nately on lysine residues. The information richness of protein
ubiquitylation is extended considerably by the fact that proteins can
bemonoubiquitylated, polyubiquitylated (chains of ubiquitin attached
to a single lysine residue) or multiubiquitylated (one or more
ubiquitins attached to different lysine residues). The utility of
ubiquitin as a post-translational signal is extended further by the
fact that ubiquitin has seven lysine residues, any of which can be used
in the formation of ubiquitin chains that are attached to proteins. For
example, ubiquitin chains formed through lysine 48 linkages are
primarily recognised by the 26S proteasome for degradation of the
polyubiquitylated target protein, while ubiquitin chains formed
through lysine 63 linkages are recognised by ubiquitin-binding
proteins involved in intracellular signalling pathways. Recent
evidence also points to the existence of ‘forked’ polyubiquitin chains
with mixed lysine linkages.
Furthermore, ubiquitin has close and distant cousins (ubiquitons),
many of which are also involved in the covalent modiﬁcation of
proteins. The tagging of proteins by ubiquitin or its cousins controls
not only protein degradation but also most processes in the cell,
including DNA synthesis and repair, cell division, transcription,
translation, organelle biogenesis, autophagy and endocytosis. It can
be conﬁdently predicted that the functions of ubiquitin and ubiquitin-
like proteins will be considerably extended in the future as new
discoveries widen the understanding of these proteinmodiﬁcations in
cell physiology.
Given this functional diversity, it is not surprising that dysfunction
of the ubiquitin proteasome system (UPS) is increasingly seen as a
major factor in human disease. In this special issue of BBA Molecular
Basis of Disease titled Ubiquitin, Proteasomes, and Disease, we have
selected topics that illustrate that defects in the UPS and other
ubiquitin-mediated processes are central to the pathophysiology of
disease in organs, including the heart, brain, skeletal muscle, kidney,
gut, skeleton, and liver as well as in infectious disease. No doubt, the
UPS will play a role in the pathogenesis of disease in all human
physiological systems.
The focus of considerable activity of the biotechnological sector
and major pharmaceutical companies is currently on protein
kinases as drug targets in view of the central role of protein
phosphorylation in cell regulation and disease, e.g., in cancer. The
enzymes involved in the UPS, including ubiquitin-activating0925-4439/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2008.09.002enzymes (E1s), ubiquitin-conjugating enzymes (E2s), ubiquitin
protein ligases (E3s) and deubiquitylating enzymes (DUBs), are
targets for drug discovery. Such drug-development programs are
necessary, given the comparable central importance of the UPS and
phosphorylation in disease pathogenesis. So far, only the protea-
some inhibitor bortezomib is licensed for treating multiple
myeloma. Other compounds are in clinical trials. There are tens of
E2s, as many as 1000 E3s, and up to a hundred DUBs, which can be
allocated into distinct families of enzymes. These enzymes appear
to work in complexes, with speciﬁc E2s working together with
partner E3s and DUBs to control different signaling pathways in the
cell. The understanding and classiﬁcation of these enzyme associa-
tions will lay the foundation for drug discovery in different human
diseases. The articles in this issue illustrate the challenges in the
dissection of these relationships in order to deﬁne precise targets
for therapeutic intervention.
Finally, it is interesting that the focus on proteases in the ﬁrst
part of the 20th century was on extracellular enzymes involved in
functions including digestion, blood clotting, the complement
system and remodelling of the extracellular matrix. In the latter
part of the 20th century and in this century the importance of
intracellular proteolysis has been established for regulated protein
degradation by the UPS and autophagy, as well as the role of the
caspase system in programmed cell death. Molecular systems
biology will characterise these intracellular proteolytic systems
more precisely, identify the molecular basis of their cooperative
interactions and point more precisely towards the molecular basis of
disease and drug discovery.
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Professor Mayer has worked on intracellular proteolysis for
40years and on theubiquitinproteasomesystem(UPS) since
1987. Early protein microinjection studies identified a
"protein sequestration site associated with the microtubule
organising centre for protein degradation by autophagy"
later better named by Ron Kopito (Stanford) as the
"aggresome". This work lead to studies on the UPS and
chronic neurodegenerative disease because all the diseases
are characterised by inclusions made of protein aggregates.
TheNottinghamgroupshowedthat inclusions inParkinson's
disease and amyotrophic lateral sclerosis contain ubiquity-
lated proteins. Additionally, these immunohistochemical
investigations led to the discovery of cortical Lewy bodies
by ubiquitin immunohistochemistry and the identification of Dementiawith Lewy bodies,
which is the second most common cause of cognitive decline in the elderly after
Alzheimer's disease. This work has now culminated in a recent publication describing the
generation by the Cre-recombinase/loxP genetic approach of the first mouse model of
dementia with Lewy bodies and a new model of Parkinson's disease by the regional
ablation of a 26S proteasome regulatory ATPase gene. An alternative approach, originally
based on yeast two-hybrid screens, searching for interaction partners with another
proteasomal ATPase, led to the discovery with Prof. Jun Fujita (Kyoto University) of
gankyrin, the first liver oncoprotein. Gankyrin is overexpressed in hepatocellular
carcinoma. Gankyrin regulates the activity of the retinoblastoma protein, p53 and NFKB
to oppose apoptosis and encourage the development of hepatocelluar carcinoma.
